Pharmaceutical Regulatory Affairs plays a pivotal role in ensuring the safety, efficacy, and quality of pharmaceutical products, acting as the liaison between pharmaceutical companies and regulatory authorities. This dynamic field navigates the complex landscape of regulations and guidelines, shaping the development, manufacturing, and marketing of drugs.
Professionals in Regulatory Affairs are responsible for interpreting and implementing regulatory requirements to ensure compliance throughout the drug development lifecycle. They work closely with cross-functional teams to strategize and execute regulatory submissions, seeking approvals from health authorities such as the FDA, EMA, and other regulatory bodies worldwide.
The regulatory landscape is ever-evolving, and Regulatory Affairs professionals stay abreast of changes, guiding companies through the intricacies of new guidelines and ensuring adherence to established standards. They contribute to the successful launch and post-marketing surveillance of pharmaceutical products, addressing challenges related to labeling, safety reporting, and product recalls.
Pharmaceutical Regulatory Affairs professionals also play a crucial role in fostering international harmonization, facilitating global drug development and access. Their expertise is instrumental in navigating the complex web of regulations, ultimately contributing to the availability of safe and effective medicines for patients worldwide.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico